The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry.
Signal Transduct Target Ther
; 6(1): 189, 2021 05 12.
Article
en En
| MEDLINE
| ID: mdl-33980808
ABSTRACT
Since the outbreak of coronavirus disease 2019 (COVID-19), it has become a global pandemic. The spike (S) protein of etiologic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specifically recognizes human angiotensin-converting enzyme 2 (hACE2) as its receptor, which is recently identified as an interferon (IFN)-stimulated gene. Here, we find that hACE2 exists on the surface of exosomes released by different cell types, and the expression of exosomal hACE2 is increased by IFNα/ß treatment. In particular, exosomal hACE2 can specifically block the cell entry of SARS-CoV-2, subsequently inhibit the replication of SARS-CoV-2 in vitro and ex vivo. Our findings have indicated that IFN is able to upregulate a viral receptor on the exosomes which competitively block the virus entry, exhibiting a potential antiviral strategy.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Replicación Viral
/
Interferón beta
/
Interferón-alfa
/
Internalización del Virus
/
Exosomas
/
Enzima Convertidora de Angiotensina 2
/
SARS-CoV-2
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Signal Transduct Target Ther
Año:
2021
Tipo del documento:
Article